Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Total transvaginal natural orifice endoscopic surgery (v-NOTES) for colon cancer: A prospective cohort pilot study.

Chenhao Huang, Yiqing Shi, Yimei Jiang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15617

e15617 Background: The abdominal incisions after laparoscopic colorectal cancer surgery remain to bother surgeons and patients due to cosmetic concerns, p...

Real-world patterns of Oncotype DX (O-Dx) testing and chemotherapy (CT) use among patients with early-stage, hormone receptor–positive (HR+) breast cancer (BC).

Marija Sullivan, Xiudong Lei, Inimfon Jackson et al. Jun 01, 2025 pp. 528-528 10.1200/jco.2025.43.16_suppl.528

528 Background: O-Dx, a 21-gene assay, has transformed the management of patients with early-stage, HR+, HER2-negative (HER2-) BC by guiding personalized...

Use of Al-based models integrating serum proteomics and clinicopathologic features to predict survival outcomes in NSCLC patients undergoing immunotherapy.

Junho Song, Young Kwang Chae, Jongwoo Kim et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14577

e14577 Background: Responses to immune checkpoint inhibitors in patients with advanced NSCLC present a wide range of outcomes. Integrating serum proteomic...

SMET12 and toripalimab combined chemotherapy in patients with advanced non-small cell lung cancer who are treatment-naive or have developed resistance to standard therapy.

Jinghui Lin, Zhiyong He, Meifang Li et al. Jun 01, 2025 pp. 8570-8570 10.1200/jco.2025.43.16_suppl.8570

8570 Background: SMET12 is a recombinant anti-EGFR and CD3 bispecific antibody independently developed by Zhejiang Shimai Pharmaceutical. This study aims...

Outcomes and predictors of chronic graft-vs-host-disease in bone marrow transplant recipients.

Samridhi Sinha, Jayalekshmi Jayakumar, Siddharth Karipineni et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18552

e18552 Background: Chronic graft-versus-host disease (GVHD) affects approximately 20-40% of transplant recipients. It is a complication mediated by alloge...

Safety and efficacy of subcutaneous versus intravenous administration of PD (L)1 inhibitors in patients with solid tumors: A systematic review and meta-analysis.

Carlotta Persaud, José Reinaldo De Oliveira Junior, Pedro C. A. Reis et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14590

e14590 Background: Intravenous (IV) administration of Programmed Cell Death 1/Ligand 1 (PD (L)1) inhibitors is the standard of care for the treatment of v...

Likelihood of unplanned readmission among oncology patients with a completed post-discharge follow-up encounter.

Emma Hannan, Adam F. Binder, Valerie Pracilio Csik Jun 01, 2025 pp. 11035-11035 10.1200/jco.2025.43.16_suppl.11035

11035 Background: Literature suggests that oncology patients are more likely to be admitted from the emergency department to the hospital than patients wi...

The impact of a pilot oncology summer internship on early medical students' understanding of oncology and social determinants of health: A mixed-methods study.

Anney Tuo Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21025

e21025 Background: As cancer diagnoses rise, there is an increasing need for medical schools to engage students in oncology. Moreover, given the associati...

Using longitudinal spatial-omics to demonstrate in-situ Epstein-Barr virus reduction in responders to immunotherapy treated nasopharyngeal cancer.

Yang Wu, Zhen Wei Neo, Li Yen Chong et al. Jun 01, 2025 pp. 6025-6025 10.1200/jco.2025.43.16_suppl.6025

6025 Background: Epstein-Barr virus (EBV) related nasopharyngeal cancer (NPC) is endemic in Southern China and Southeast Asia. Limited studies of tumor-im...

Vincristine and topotecan versus carboplatin-, etoposide-, and vincristine-based chemotherapy for ocular salvage in group D and group E intraocular retinoblastoma: A randomized, comparative trial.

Prashant Prabhakar, Kritika Setlur, Debabrata Mohapatra et al. Jun 01, 2025 pp. 10002-10002 10.1200/jco.2025.43.16_suppl.10002

10002 Background: India has the highest burden of retinoblastoma worldwide. The access to Intra-arterial chemotherapy is limited and systemic chemotherapy...

Association of inflammation with depression in pancreatic ductal adenocarcinoma.

Junmin Song, Daniel Hyosung Hong, Sion Park et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e24059

e24059 Background: Pancreatic ductal adenocarcinoma (PDAC) exhibits the highest rates of depression, cachexia, and inflammation among cancers. Systemic in...

Regional and demographic trends in mortality from breast cancer and respiratory diseases in United States from 1999-2019: A retrospective analysis.

Muhammad Imaz Bhatti, Roshan Afshan, Muhammad Atif Bashir et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13779

e13779 Background: Breast cancer and respiratory diseases are significant contributors to global morbidity and mortality, particularly in vulnerable popul...

NG11-2 phase-Ib trial to prevent/reduce severe oral mucositis induced by radiotherapy.

Mary Lei, Rafael Moleron, Andrew G. J. Hartley et al. Jun 01, 2025 pp. 12121-12121 10.1200/jco.2025.43.16_suppl.12121

12121 Background: Radiation-induced oral mucositis (RIOM) affects up to 80% of people undergoing treatment for head and neck cancer (HNC), reaching nearly...

Correlation of elevated CA19-9 and cancer associated macrophages in blood with outcomes in pancreatic cancer patients over 5 years.

Aravind Aryasomayajula, Susan Tsai, Mohammed Aldakkak et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16464

e16464 Background: Pancreatic cancer (PC) is a highly aggressive cancer accounting for ~7% of all cancer related deaths in the United States. In PC, Carbo...

Efficacy and safety of immune checkpoint inhibitors in patients with unresectable metastatic colon cancer with microsatellite instability high or mismatch repair deficiency: A systematic review and meta-analysis.

Shariq Ahmad Wani, Allahdad Khan, Kamran Habib et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15543

e15543 Background: Metastatic colon cancer (mCRC) characterized by microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) status in s...

Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial.

Rita Mukhtar, Katrina Dimitroff, Christina Yau et al. Jun 01, 2025 pp. 504-504 10.1200/jco.2025.43.16_suppl.504

504 Background: Axillary surgery in breast cancer is used for staging and therapeutic purposes, but axillary lymph node dissection (ALND) confers high ris...

Effect of external beam radiotherapy on hepatic parenchymal resection rate.

Bin Shu, Ying Zhao, Haoming Xia et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16315

e16315 Background: The hepatic parenchymal resection rate (HPRR), defined as the percentage of tumor-bearing liver volume relative to total liver volume,...

A phase I/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer.

Yuan Yuan, Jin Sun Bitar, MaLia Walker et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13146

e13146 Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastati...

Clinical characteristics and acute side effects of salvage radiotherapy in biochemical recurrence of prostate cancer: A retrospective cohort study.

Nicole Arbex, Pedro Umpierre, Ramon Ferrari et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17004

e17004 Background: Biochemical recurrence (BCR) following radical prostatectomy poses a significant challenge in the management of prostate cancer. Salvag...

Prognostic factors in thyroid cancer patients with brain metastases: A systematic review and individual patient data meta-analysis.

Hamza Salim, Ahmed Msherghi, Mohamed Farouq Alsharedi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14004

e14004 Background: Brain metastases (BM) from thyroid cancer (TC) are rare but signify an advanced stage of the disease with poor survival outcomes. This...

Therapeutic decisions and outcome of patients with stage I testicular germ cell tumor: Single-centre experience.

Isabella Cavaglià, Patrizia Lista, Roberto Filippi et al. Jun 01, 2025 pp. 5029-5029 10.1200/jco.2025.43.16_suppl.5029

5029 Background: Testis cancer (TC) is the most common solid neoplasm affecting men aged 15 to 40, with most of diagnosis occurring at stage I. Despite ex...

Unveiling demographic and socioeconomic patterns in hidradenocarcinoma: A retrospective National Cancer Database study.

Sadaf Sadighian, Assal Sadighian, Suraj Puvvadi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21580

e21580 Background: Hidradenocarcinoma is a rare and malignant tumor arising from the eccrine or apocrine sweat glands. Hidradenocarcinoma has the potentia...

SEQUOIA 5-year follow-up in arm C: Frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Constantine Si Lun Tam, Paolo Ghia, Mazyar Shadman et al. Jun 01, 2025 pp. 7011-7011 10.1200/jco.2025.43.16_suppl.7011

7011 Background: Zanubrutinib (zanu) is a next-generation Bruton tyrosine kinase inhibitor that is approved for 5 indications, including CLL/SLL. Initial...

Diagnostic and prognostic applications of blood cadherin-17 (CA17) and CA19.9 on pancreatic cancer.

William C.S. Cho, Felix Hon, Mandy Lok-Yi Li et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16459

e16459 Background: The asymptomatic nature of pancreatic cancer (PC) poses significant challenges for effective initial evaluation of suspected cases. Con...

Single-institution experience using bevacizumab for <i>IDH1/2</i> -mutant gliomas.

Collin Le, Chuyin Yang, Blaine S.C. Eldred et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14031

e14031 Background: Bevacizumab (Bev), a monoclonal antibody that inhibits vascular endothelial growth factor, was fully FDA-approved in 2017 for use in re...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page